* Biocept Inc BIOC.OQ BIOC.O is expected to show a rise in
quarterly revenue when it reports results on November 15.
* The San Diego, California-based company is expected to report
a 144.0% increase in revenue to $16.071 million from $6.59
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Biocept Inc is for
earnings of 7 cents per share. For the same quarter last year,
the company reported a loss of 43 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Biocept Inc is
$13, about 70.6% above its last closing price of $3.82.
This summary was machine generated November 12 at 22:23 GMT.
All figures in US dollars unless otherwise stated